New drug cocktail aims to tame tough leukemias
NCT ID NCT07604233
First seen Jun 13, 2026 · Last updated Jun 23, 2026 · Updated 3 times
Summary
This study tests a combination of seven drugs (including asciminib and venetoclax) in 30 adults with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute myeloid leukemia. The first phase checks safety, and the second phase sees if the combo helps control the disease. Participants receive the drugs intravenously, by injection, or orally.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT MD Anderson
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fludarabine, cytarabine, idarubicin, filgrastim, venetoclax, asciminib, blinatumomab
What this could lead to
If successful, this could offer a more effective treatment option for patients with advanced phases of chronic myeloid leukemia and Philadelphia chromosome-positive acute myeloid leukemia.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply to everyone. The combination of multiple drugs may cause significant side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.